
Coronavirus COVID-19 Clinical Picture and Management



Dr Abdul Monem HAMID Professeur Associé Service de Pneumologie et Transplantation Pulmonaire Hôpital FOCH PARIS 21 march 2020







Clinical picture and management

KEY POINTS

- Clinical presentation
- Risk factors
- Diagnostic criteria
- > Initial investigations
- Manangement
 - Supportive care
 - medical therapy
- Conclusion

Clinical Presentation

History

- Take a detailed history to ascertain the level of risk for COVID-19 and assess the possibility of other causes.
- Travel history may be key; it is crucial for timely diagnosis and to prevent further transmission.
- > The diagnosis should be suspected in patients with :
 - fever and/or signs/symptoms of acute respiratory illness (e.g., cough, dyspnoea)
 - who reside in or have travelled to a country/area or territory reporting local transmission of COVID-19 or
 - who report close contact with a confirmed or probable case of COVID-19 in the 14 days prior to symptom onset

Clinical presentation

fever≥38 c





cough



Chen et al The Lancet 2020 S0140-6736(20)30211-7

dyspnoea

如果您在14天内去过任何一个疫区 如果您有发热,咳嗽或呼吸困难 请立即告知医院接待处

CORONAVIRUS

COVID 19

新型冠状病毒

Vous revenez depuis moins de 14 jours d'une zone où circule le virus. Vous avez de la fièvre, vous toussez ou vous avez du mal à respirer : Merci de le signaler à l'accueil dès votre arrivée et d'éviter les contacts avec d'autres personnes. If symptoms appeared within 14 days following

your return from an infected aera, if you have fever and cough or have trouble breathing: Please notify us immediately.

التاه رجوعك أو سفرك لمنطقة انتشر فيها فيروس كورونا عن مدة لا تقل عن ١٤ يومًا: لديك حمى أو سعال أو لديك مشكلة في التنفس يرجى إبلاغ مكتب الاستقبال عند الوصول وتجنب الانصال مع الأخرين.



Clinical Presentation

most common symptoms

- ✓ Fever 99%
- ✓ Cough 59%
- ✓ Dyspnoea 31%
- ✓ Myalgia 35%
- ✓ Fatigue 60%

Less common symptoms

- ✓ Anorexia
- ✓ Sputum production
- \checkmark Sore throat
- ✓ Confusion
- ✓ Dizziness
- ✓ Headache
- ✓ Rhinorrhoea
- \checkmark Chest pain
- ✓ Haemoptysis
- ✓ Diarrhoea
- ✓ Nausea/vomiting
- ✓ Abdominal pain
- ✓ Conjunctival congestion

Wang d, and all, JAMA. 2020 Feb 7 [Epub ahead of print] Chen et al The Lancet 2020 S0140-6736(20)30211-7

TABLE I: Basic Clinical and Epidemic Features		
Feature	All Patients (n = 101)	
Sex		
Male	56 (55.4)	
Female	45 (44.6)	
Age (y)		
Mean	44.44	
Range	17–75	
Age group (y)		
≤ 20	1 (1.0)	
21-40	44 (43.6)	
41-50	27 (26.6)	
51-60	14 (13.9)	
61-70	14 (13.9)	
≥ 70	1 (1.0)	
Epidemiologic history		
Direct exposure	84 (83.2)	
Indirect exposure	12 (11.9)	
No exposure	5 (4.9)	
Onset symptoms		
Fever	79 (78.2)	
Cough	63 (62.4)	
Myalgia or fatigue	17 (16.8)	
Sore throat	12 (11.9)	
Dyspnea	1 (1.0)	
Diarrhea	3 (3.0)	
Nausea and vomiting	2 (2.0)	
More than one symptom	67 (66.3)	
None	2 (2.0)	
Underlying disease ^a		
Cardiovascular and cerebrovascular diseases	16 (15.8)	
Surgical history	7 (6.9)	
Digestive system disease	6 (5.9)	
Respiratory system disease	5 (4.9)	
Endocrine system disease	3 (3.0)	
None	71 (70.3)	

Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study

Zhao et al, AJR:215, February 18, 2020

Table 1. Clinical Characteristics of the Study Patients, According to	Disease Severity and	the Presence or Abser	ice of the Primary Coi
	All Patients		
Characteristic	(N = 1099)	Disease	
		Nonsevere (N=926)	Severe (N=173)
Age		(
Median (IQR) — yr	47.0 (35.0-58.0)	45.0 (34.0-57.0)	52.0 (40.0-65.0)
Distribution — no./total no. (%)			
0–14yr 15–49 yr	9/1011 (0.9)	8/848 (0.9)	1/163 (0.6)
15-49 yr 50-64 yr	557/1011 (55.1) 292/1011 (28.9)	490/848 (57.8) 241/848 (28.4)	67/163 (41.1) 51/163 (31.3)
≥65 yr	153/1011 (15.1)	109/848 (12.9)	44/163 (27.0)
Female sex — no./total no. (%)	459/1096 (41.9)	386/923 (41.8)	73/173 (42.2)
Smoking history — no./total no. (%)			
Never smoked	927/1085 (85.4)	793/913 (86.9)	134/172 (77.9)
Former smoker Current smoker	21/1085 (1.9) 137/1085 (12.6)	12/913 (1.3) 108/913 (11.8)	9/172 (5.2) 29/172 (16.9)
Exposure to source of transmission within past 14 days — no./	137/1085 (12.0)	100/915 (11.0)	23/172 (10.3)
total no. Living in Wuhan	483/1099 (43.9)	400/926 (43.2)	83/173 (48.0)
Contact with wildlife	13/687 (1.9)	10/559 (1.8)	3/128 (2.3)
Recently visited Wuhan:	193/616 (31.3)	166/526 (31.6)	27/90 (30.0)
Had contact with Wuhan residents:	442/611 (72.3)	376/522 (72.0)	66/89 (74.2)
Median incubation period (IQR) — days§	4.0 (2.0-7.0)	4.0 (2.8–7.0)	4.0 (2.0-7.0)
Fever on admission	172 (3 003 (12 0)		
Patients — no./total no. (%) Median temperature (IQR) — °C	473/1081 (43.8) 37.3 (36.7-38.0)	391/910 (43.0) 37.3 (36.7–38.0)	82/171 (48.0) 37.4 (36.7-38.1)
Distribution of temperature — no./total no. (%)	57.5 (50.7-50.0)	57.5 (50.7-50.0)	57.4 (50.7-50.2)
<37.5°C	608/1081 (56.2)	519/910 (57.0)	89/171 (52.0)
37.5–38.0°C	238/1081 (22.0)	201/910 (22.1)	37/171 (21.6)
38.1–39.0°C	197/1081 (18.2)	160/910 (17.6)	37/171 (21.6)
>39.0°C	38/1081 (3.5)	30/910 (3.3)	8/171 (4.7)
Fever during hospitalization Patients — no./total no. (%)	975/1099 (88.7)	816/926 (88.1)	159/173 (91.9)
Median highest temperature (IQR) — °C	38.3 (37.8-38.9)	38.3 (37.8-38.9)	38.5 (38.0-39.0)
<37.5°C	92/926 (9.9)	79/774 (10.2)	13/152 (8.6)
37.5–38.0°C	286/926 (30.9)	251/774 (32.4)	35/152 (23.0)
38.1–39.0°C	434/926 (46.9)	356/774 (46.0)	78/152 (51.3)
>39.0*C	114/926 (12.3)	88/774 (11.4)	26/152 (17.1)
Symptoms — no. (%)			
Conjunctival congestion	9 (0.8)	5 (0.5)	4 (2.3)
Nasal congestion	53 (4.8)	47 (5.1)	6 (3.5)
Headache Cough	150 (13.6) 745 (67.8)	124 (13.4) 623 (67.3)	26 (15.0) 122 (70.5)
Sore throat	153 (13.9)	130 (14.0)	23 (13.3)
Sputum production	370 (33.7)	309 (33.4)	61 (35.3)
Fatigue	419 (38.1)	350 (37.8)	69 (39.9)
Hemoptysis	10 (0.9)	6 (0.6)	4 (2.3)
Shortness of breath	205 (18.7)	140 (15.1)	65 (37.6)
Nausea or vomiting	55 (5.0)	43 (4.6)	12 (6.9)
Diarrhea	42 (3.8)	32 (3.5)	10 (5.8)
Myalgia or arthralgia	164 (14.9)	134 (14.5)	30 (17.3)
Chills Signs of in fection — no. (%)	126 (11.5)	100 (10.8)	26 (15.0)
Signs of infection — no. (%) Throat congestion	19 (1.7)	17 (1.8)	2 (1.2)
Tonsil swelling	23 (2.1)	17 (1.8)	6 (3.5)
Enlargement of lymph nodes	2 (0.2)	1 (0.1)	1 (0.6)
Rash	2 (0.2)	0	2 (1.2)
Coexisting disorder — no. (%)			
Any	261 (23.7)	194 (21.0)	67 (38.7)
Chronic obstructive pulmonary disease	12 (1.1)	6 (0.6)	6 (3.5)
Diabetes	81 (7.4)	53 (5.7)	28 (16.2)
Hypertension	165 (15.0)	124 (13.4)	41 (23.7)
Coronary heart disease	27 (2.5)	17 (1.8)	10 (5.8)
Cerebrovascular disease	15 (1.4)	11 (1.2)	4 (2.3)
Hepatitis B infection¶ Cancer	23 (2.1) 10 (0.9)	22 (2.4) 7 (0.8)	1 (0.6) 3 (1.7)
Cancer] Chronic renal disease	8 (0.7)	5 (0.5)	3 (1.7)
Immunodeficiency	2 (0.2)	2 (0.2)	0
	- (•)	- (***)	

The NEW ENGLAND JOURNAL of MEDICINE

Clinical Characteristics of Coronavirus Disease 2019 in China

- 1. Most of the patient cohort hospitalized did not initially have fever 2. median age 47, and 42% were women.
- 3. 25% had a preexisting condition, such as hypertension or COPD.
- 4.patients with severe disease were older than the non-severe patients
- 5. 5% were admitted to the ICU, 2.3% required mechanical ventilation, and 1.4% died.
- 6. Cough 60%, 40% presented with fever, all developed fever while hospitalized.
- 7. 16% of patients developed "severe illness" after admission
- 8. 80% of patients had lymphocytopenia at admission, and most had elevated C-reactive protein.
- 9. median incubation 4 days.
- 10. ground-glass opacity was the most common on chest CT ,18% of nonsevere cases, no radiographic or CT abnormality was found.
- 11. 60% of patients received IV antibiotics, 35% received oseltamivir therapy. 40% required oxygen therapy.

12. Patients stayed in the hospital for a median of 12 days, during which time most received a diagnosis of pneumonia.

Severity and Risk factors

> The clinical presentation resembles viral pneumonia

severity of illness ranges from :

- ✓ Mild 80%
- ✓ Severe 14%
- ✓ Critical illness 5 %
- ✓ Minimally symptomatic or asymptomatic

Illness severity is associated with :

- ✓ older age
- ✓ Presence of underlying health conditions :
- hypertension
- diabetes
- cardiovascular disease
- respiratory disease

Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 17;41(2):145-51 Yang, J, Int J Infect Dis. 2020 Mar 12 [Epubahead of print].

Initial investigations

- Pulse oximetry
- > ABG (as indicated to detect hypercarbia or acidosis)
- > FBC
- Comprehensive metabolic panel
- Coagulation screen
- Inflammatory markers (serum procalcitonin and C-reactive protein)
- Serum troponin
- Serum lactate dehydrogenase
- Blood and sputum cultures
- Serum creatine kinase

Qin C, Zhou L, Hu Z, et al. Wuhan, China. Clin Infect Dis. 2 020 Mar 12 [Epub ahead of print].

Test	Result	
 pulse oximetry Order in patients with severe illness. Recommended in patients with respiratory distress and cyanosis. 	may show low oxygen saturation (SpO ₂ <90%	
 ABG Order in patients with severe illness as indicated to detect hypercarbia or acidosis. Recommended in patients with respiratory distress and cyanosis whe have low oxygen saturation (SpO₂ <90%). 	may show low partial oxygen pressure	
 FBC Order in patients with severe illness. The most common laboratory abnormalities in patients hospitalised with pneumonia include leukopenia, lymphopenia, and leukocytosis. Other abnormalities include neutrophilia, thrombocytopenia, and decreased haemoglobin.[6] [7] [8] [81] 	leukopenia; lymphope leukocytosis	
 coagulation screen Order in patients with severe illness. The most common abnormalities are elevated D-dimer and prolonge prothrombin time.[6] [7] [8] Non-survivors had significantly higher D-dimer levels and longer prothrombin time and activated partial thromboplastin time compare with survivors in one study.[95] 		
 comprehensive metabolic panel Order in patients with severe illness. The most common laboratory abnormalities in patients hospitalised with pneumonia include elevated liver transaminases. Other abnormalities include decreased albumin and renal impairment.[6] [Liver function abnormalities may be more common in patients with COVID-19 compared with other types of pneumonia.[91] 	elevated liver transaminases; decreased albumin; re impairment 7]	
 serum procalcitonin Order in patients with severe illness. May be elevated in patients with secondary bacterial infection.[6] [7] May be more common in children.[77] 	may be elevated	
 serum C-reactive protein Order in patients with severe illness. May be elevated in patients with secondary bacterial infection.[6] [7] 	may be elevated	
 serum lactate dehydrogenase Order in patients with severe illness. Elevated lactate dehydrogenase has been reported in 73% to 76% of patients.[6] [7] May be more common in patients with COVID-19 compared with other types of pneumonia.[91] Indicates liver injury or lysis of blood erythrocytes. 	may be elevated	
serum creatine kinase	may be elevated	
 Order in patients with severe illness. serum troponin level Order in patients with severe illness. May be elevated in patients with cardiac injury.[6] 	may be elevated	
blood and sputum cultures	negative for bacterial	
 Collect blood and sputum specimens for culture in all patients to rule out other causes of lower respiratory tract infection and sepsis, especially patients with an atypical epidemiological history.[5] Specimens should be collected prior to starting empirical antimicrobials if possible. 	infection	
 real-time reverse transcription polymerase chain reaction (RT-PCR) Molecular testing is required to confirm the diagnosis. Nucleic acid sequencing may be required to confirm the diagnosis.[83] Collect upper respiratory specimens (nasopharyngeal and oropharyngeal swab or wash) in ambulatory patients and/or lower respiratory specimens (sputum and/or endotracheal aspirate or 	positive for severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) viral RNA; may be positive for influenza A and B viruses and other respiratory pathogens	

Initial investigations



BMJ Publishing Group Ltd 2020. Last updated: Mar 18, 2020

Case Report : COVID19


d1



46-yer-old man Lung Transplatation 9 years ago

Fever[•]dypnea,dry coughs Tacrolimus, MMF, Pred

> RSV – Influenza – PCR covid19 – ATB, O2____



(PCR) testing may not return positive initially

PCR covid19 + BAL ATB, O2 Mechanical ventilation NAD Ventral Decubutus **Corticosteroids ??**

d5



d6



Hôpital FOCH, Dr HAMID

Manangement of COVID 19

- ➢ Isolation
- Supportive care
- Medical therapy

Initial		(summary)
suspected COVID-19		
	1st	infection prevention and control procedures
	plus	supportive care plus monitoring
	plus	empirical antimicrobials
Acute		(summary)
confirmed COVID-19		
····· ■ severe illness	1st	hospital admission and infection prevention and control procedures
	plus	supportive care plus monitoring
	adjunct	mechanical ventilation
	adjunct	experimental therapies
····· ■ mild illness	1st	consider home care and isolation
	plus	supportive care plus monitoring

No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2.

BMJ Publishing Group Ltd 2020. Last updated: Mar 18, 2020

Medical Therapy










INTERIM CLINICAL GUIDANCE FOR PATIENTS SUSPECTED **OF/CONFIRMED WITH COVID-19 IN BELGIUM**

19 March 2020; Version 4

Treatement for COVID 19			
Drug	Clincal Studies	Mechanisme of action	
REMDESIVIR used against Ebola	ongoing	Interaction with viral polymerase	
Chloroquine Phosphate Used for malaria	ongoing	Inertaction with ACE2 receptor Immunomodulation	
Hydroxy-Chloroquine Used for lupus	ongoing		
Lopinavir/ritonavir (Kaletra) sused in VIH	ongoing	protease inhibition	

Chin Med J (Engl). 2020 Mar 5 (Epub ahead of print)


European clinical trial



https://www.sciencesetavenir.fr/sante/coronavirus-lancement-d-un-essai-cliniquesur-3-200-patients-atteint-de-covid-19-testera-des-traitements 142386


A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen



March 18, 2020 DOI: 10.1056/NEJMoa2001282


A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19



Patients assigned to lopinavir–ritonavir did not have a time to clinical improvement different from that of patients assigned to standard care alone

March 18, 2020 DOI: 10.1056/NEJMoa2001282

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19




In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir– ritonavir treatment beyond standard care

Treatment with lopinavir–ritonavir was not associated with a difference from standard care in the time to clinical improvement

Mortality at 28 days was similar in the lopinavir-ritonavir group and the standard-care group

March 18, 2020 DOI: 10.1056/NEJMoa2001282


Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial



hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.

Gautret et al. IJAA– In Press 17 March 2020 –DOI : 10.1016/j.ijantimicag.2020.105949

Anti-HCV, nucleotide inhibitors, repurposing against COVID-19



A.A. Elfiky, *Life Sciences*(2020), https://doi.org/10.1016/j.lfs.2020.117477

Take home message

- The 2019 novel coronavirus, called 'SARS-CoV-2' is a new strain that has not been identified in humans before. The disease that is caused by SARS-CoV-2 is called COVID-19
- > The clinical presentation resembles viral pneumonia, Fever, Cough, and Dyspnoea
- The severity of illness ranges from mild to severe, Illness severity is associated with older age and the presence of underlying health conditions. hypertension, diabetes, cardiovascular disease, and respiratory disease.
- > No specific treatments are known to be effective for COVID-19 yet
- Treatment protocols and clinical studies ongoing for COVID-19 in Europe, China, USA
- Patients should be managed in a hospital setting where possible; however, home care may be suitable for selected patients with mild illness unless



CORONA VIRUS

KNOW YOUR CORONA ZONE

RED ZONE

Public Areas e.g. Shops, Restaurants

Work Areas including general hospital environment, Corridors, Wards

Bright Red: Airplanes, Patient hospital rooms, High patient throughout clinic areas

ORANGE ZONE

Cars, Personal Offices GREEN ZONE

Home